H2O Innovations to buy technology, coagulants lineup from Clearlogx
Company boosts its water treatment capabilities with deal
QUEBEC CITY—H2O Innovation Inc., a water treatment and membrane filtration company, has announced it will acquire Clearlogx Inc.’s assets pertaining to its unique control technology and its specialty coagulants.
The company said the proprietary technology precisely controls the feed of coagulants used in water treatment to maintain a proper pH level and an optimum particle charge, while simultaneously improving overall treatment process efficiency. It noted the technology is critical for ultrafiltration water treatment plants to minimize membrane fouling, something that is highly complementary to H2O Innovation’s business.
“This acquisition fits perfectly with H2O Innovation’s vision to complement its offering to its customers and to create synergies between its different business lines,” Frédéric Dugré, president and CEO of H2O Innovation, said. “This new business unit will undoubtedly contribute to the growth and profitability of H2O Innovation by complementing its offering, generating more recurrent sales and bringing differentiation.”
In addition to the technology, H2O will acquire Clearlogx’s coagulant-related business.
“This line of specialty coagulants is complementary to the Corporation’s specialty chemicals marketed under the name PWTTM and will significantly increase the level of recurrent sales,” the company said.
H2O innovation said the deal will be entirely financed by a US$2 million loan from a Canadian chartered bank, but did not disclose the exact details about the transaction. The deal is expected to close at the beginning of October.